Abstract: Matrix 2 protein ectodomain (M2e) of influenza virus appears to be a promising vaccine candidate because its sequence is highly conserved among virus strains. However, M2e is too meager to induce a strong immune response by itself. Several approaches are being used to increase the antigenicity of M2e. In an effort to enhance the M2e-specific immune response, we generated a TAT-conjugated M2e recombinant protein. Seven-week-old BALB/c mice were divided into three groups and transcutaneously immunized with 100 μg TAT-8×M2e (TAT conjugated with eight copies of M2e) and 8×M2e (eight copies of M2e) proteins on days 1, 15 and 29. The control mice were injected with PBS on the same days. Antibody titers specific for M2e were measured using indirect ELISA. Mice immunized with the TAT-8×M2e and 8×M2e proteins developed almost the same levels of M2e-specific total IgG and IgG1 antibodies. However, a higher level of M2e-specific IgG2a was observed in mice immunized with TAT-8×M2e than in those immunized with 8×M2e. These results suggest that TAT has an adjuvant effect that induces a Th1-type immune response. Therefore, the TAT-M2e vaccine can be applied to animals as a new influenza vaccine for enhancement of Th1-type immune responses.
INTRODUCTION
Influenza remains one of the most serious infectious diseases and causes high morbidity and mortality worldwide. Annual vaccination is the most effective way to prevent influenza virus infection [11] . Production of an annual influenza vaccine requires that the virus strain be predicted on the basis of virus surveillance data collected by the World Health Organization (WHO). Influenza virus, a member of the Orthomyxoviridae family, has a negativesense single-stranded RNA genome. The virus genome comprises eight segmented RNAs and encodes 11 proteins [19] . Hemagglutinin (HA) and neuraminidase (NA) are major structural proteins. Antibodies against HA act as neutralizing antibodies. On the other hand, due to the antigenic shift and antigenic drift of influenza virus, production of effective vaccines remains challenging [5] . In order to overcome these problems, a universal influenza vaccine that provides broad protection against almost all types of influenza viruses is needed.
Matrix 2 (M2) protein is a promising antigen for development of a universal influenza vaccine [10] . M2 protein is scarcely present on virus particles but abundant in virusinfected cells [27] . M2 forms a tetrameric proton channel and induces uncoating of the virus. M2 protein comprises a short N-terminal ectodomain, transmembrane domain, and endodomain. The sequence of the M2 ectodomain (M2e), composed of 24-amino acids, is highly conserved among influenza strains, including the 1918 pandemic strain [21] . Therefore, a vaccine targeting M2e could be a universal influenza vaccine and provide cross-protection against a broad range of influenza viruses.
However, M2e induces poor antibody responses. Therefore, several approaches aimed at improvement of immune responses against M2e have been attempted. For example, M2e protein conjugated with the flagellin of Salmonella typhimurium, a TLR-5 ligand, was used to potentiate the immunogenicity of M2e vaccine [13] . M2e fused with the CTA1-DD adjuvant, the cholera toxin subunit A, induces strong protective immunity [8] . Hepatitis B virus core (HBc) particle was also used as a carrier of M2e. These vaccines induce M2e-specific antibodies which mediate antibody-dependent cell-mediated cytotoxicity (ADCC) [6] . ADCC plays an important role in protection of the host from lethal influenza infection.
The repetitive arrangement of a single M2e enhances B-cell response; in addition, the trans-activator of transcription (TAT) of human immunodeficiency virus (HIV) is expected to improve cell-mediated immune response [16] . TAT is a protein transduction domain (PTD) that can transduce biologically active proteins across the plasma membrane, allowing accumulation of such proteins within the cytoplasm and nucleus [25] . A basic domain of the TAT protein (aa 37∼72) promotes the transduction of cargo proteins, although there are cargo-dependent variations in transduction efficiency [9] . Transmembrane transduction by these PTDs occurs via a kind of endocytosis mechanism using cell-surface heparin proteoglycans as portals [20] . When a PTD-conjugated fusion protein enters the cell, it is expected to be presented on MHC class I molecules via the cytosolic pathway and to induce a T-cell-mediated immune response [2] .
In this study, eight copies of M2e (8×M2e) fused to TAT were generated in order to improve the immunogenicity of M2e and the immune response was evaluated in mice immunized with the protein.
MATERIALS AND METHODS

Cloning
Two copies of the influenza M2e based on a previously reported sequence [10] and restriction enzyme sites (BglII and HindIII) were synthesized and cloned into the pGEM-T easy vector (Promega, USA) by Bioneer Inc. (Korea). In this synthetic gene, cysteine residues were modified to serine for compatible expression in prokaryotic systems (SLLTE-VETPIRNEWGSRSNDSSDP). The M2e plasmid was digested with BamHI (NEB, England) and HindIII (NEB, England). The digested insert DNA fragment was ligased into the plasmid, which was digested with BglII (NEB, England) and HindIII, to make four copies of M2e (4×M2e) and transformed into DH5α competent cells (RBC TM , Taiwan). In the same way, the 4×M2e plasmid was digested with BamHI and HindIII and this insert DNA fragment was ligased in the plasmid, which was digested with BglII and HindIII (Fig.  1A) . Finally, the 8×M2e plasmid was constructed (Fig. 1B) . Every construct was screened by restriction enzyme digestion and confirmed by sequence analysis. HIV TAT (GRKKRRQRRRPPQC) was also synthesized and cloned into pQE30 UA vector (Qiagen, Hilden, Germany). 8×M2e was digested with SphI and HindIII and subcloned into the TAT pQE 30 UA expression vector in order to make the recombinant TAT-8×M2e vaccine product (Fig. 1C) . This plasmid was also digested with BamHI alone and self-ligased in order to make 8×M2e protein for controls. Ligation products were transformed into DH5α competent cells, screened by PCR, and confirmed by DNA sequencing. The cloned DNA sequence was determined using an ABI PRISM BigDye TM Terminator Cycle Sequencing Kit with an ABI PRISM 3730XL Analyzer (Applied Biosystems, Foster City, CA, USA).
Expression and purification of recombinant proteins
TAT-8×M2e and 8×M2e proteins were expressed and purified using the QIAexpressionist system (Qiagen). Both TAT-8×M2e pQE30 and 8×M2e pQE 30 plasmids were transformed into M15 competent cells (Qiagen) for expression. Transformants were picked and grown in 1 L LB medium with ampicillin (100 μg/ml) and kanamycin (25 μg/ml) at 37℃ and induced by 1 mM IPTG to OD600=0.6.
Four hours after induction, the cells were harvested by centrifugation and resuspended with lysis buffer (100 mM NaH2PO4, 10 mM Tris Cl, 8 M urea [pH 8.0]) at 5 ml/g wet weight. After stirring at room temperature for 1 h, lysates were centrifuged at 10,000×g for 30 min at room temperature in order to pellet the cellular debris. Supernatants were collected and purified using Ni-NTA Super flow (Qiagen) according to the manufacturer's instructions. Then, 50% Ni-NTA slurry was added to the lysates at a 1:4 ratio and mixed gently by shaking at room temperature for 1 h. Lysate-resin mixtures were loaded into an empty column and flowed out. Resins were washed twice with washing buffer (100 mM NaH 2 PO 4 , 10 mM Tris · Cl, 8 M urea [pH 6.3]). Recombinant proteins bound to nickel were eluted with elution buffer (100 mM NaH2PO4, 10 mM Tris · Cl, 8 M urea [pH 4.5]). Samples were pooled at every step of purification and subjected to SDS-PAGE and Coomassie blue staining.
Dialysis of denatured proteins
The eluted proteins were subjected to stepwise dialysis for refolding of the denatured proteins and for removal of urea. A dialysis tube (Spectrum Labs, USA) was incubated in D. W. for 30 min, followed by addition of 1 ml purified protein. The dialysis tube was then stirred in a beaker with 100 mM NaH2PO4, 10 mM Tris · Cl and 6 M urea. After 1 h, half of the buffer was removed and an equal volume of dialysis buffer (100 mM NaH2PO4 and 10 mM Tris · Cl) was added, lowering the concentration of urea to 3 M. In the same manner, the concentration of urea was lowered until it was almost 0.75 M. The dialysis buffer was finally changed to 100 mM NaH 2 PO 4 and 10 mM Tris · Cl and incubated overnight at 4℃. Dialyzed samples were subjected to SDS-PAGE and stained with Coomassie blue in order to confirm protein integrity (data not shown).
Western blot analysis of purified proteins
Purified proteins were identified by western blotting using anti-His antibody (Qiagen) and influenza H1N1-positive chicken serum. Elution samples of TAT-8×M2e and 8×M2e protein were diluted in the SDS-PAGE sample buffer containing β-mercaptoethanol. These samples were boiled for 5 min, loaded onto a 12% SDS polyacrylamide gel, and electrophoresed. After electrophoresis, separated proteins were transferred to nitrocellulose membranes (Whatman, Germany). Membranes were placed in blocking solution (5% skim milk in PBS-T) overnight at 4℃. After washing three times with PBS-T, the membranes were incubated with anti-His monoclonal antibody (Qiagen) diluted 1,000 times in 2.5% skim milk PBS-T or influenza H1N1-positive chicken serum diluted 500 times in the same buffer for 90 min at room temperature. HRP-conjugated anti-mouse IgG and HRP-conjugated anti-chicken IgG were used as secondary antibodies at 1:10,000 dilutions in 2.5% skim milk PBS-T. After incubation for 1 h, DAB in PBS-T and H 2 O 2 was added for development.
Mice and immunization
Six-week-old BALB/c mice were purchased from Oriental Bio (Korea). The mice were divided into three groups (n=8 per group) and immunized transcutaneously with 100 μg purified TAT-8×M2e protein, 8×M2e protein, or PBS as a control on days 1, 15, and 29. For efficient antigen delivery, the dorsal surface of each mouse was shaved before application of vaccine.
Serum antibody determination
Specific anti-M2e antibody titers were measured using an indirect ELISA. Ninety six-well plates (SPL, Korea) were coated with 100 μl of purified 8×M2e protein (10 μg/ml) solution in 50 mM sodium bicarbonate buffer [pH 9.7] and incubated overnight at 4℃. The plates were washed three times with 350 μl PBS-T (0.05% Tween 20 in PBS) and then blocked with 5% skim milk in PBS-T at 37℃ for 2 h. After washing three times, serum samples of immunized mice diluted 1:40 in 2.5% skim milk in PBS-T were loaded onto the plates and incubated for 90 min at 37℃. After three washes, the bound antibodies were detected with HRP-conjugated anti-mouse IgG diluted 1:10,000 in 2.5% skim milk in PBS-T. After incubation at 37℃ for 1 h, the plates were washed and incubated for 5 min with 100 μl tetramethylbenzidine (TMB) solution (Kirkegaard & Perry Laboratories, USA). The reaction was stopped by addition of an equal volume of 2 M H2SO4 and the OD at 450 nm was measured. The cut off for each test was set as twice the mean plus three standard deviations of the negative control samples. After detection of total anti-M2e IgG titer, anti-M2e IgG1 and anti-M2e IgG2a titers were also measured. For detection of IgG1 and IgG2a in the serum samples, 10,000-fold-diluted goat anti-mouse IgG1-HRP and IgG2a-HRP were added to the plates, which were incubated with 40-fold diluted serum samples, respectively. The other experimental conditions were the same as those described for detection of IgG antibody.
MDCK whole-cell ELISA
Whole-cell ELISA was performed for determination of whether the induced antibody response of immunized mice recognizes native viral M2. MDCK cells were grown in 96-well culture plates (Greiner, Germany) in MEM complete medium containing 8% FBS at 37℃ for one day. The next day, the cells were infected with 50 μl influenza virus A/NWS/33 (H1N1) at 10 6 TCID50/ml and incubated for 1 h. Then, 50 μl MEM with 2% FBS was added to each well. The next day, the wells were washed with PBS and fixed with 10% formalin for 15 min at room temperature. The wells were washed three times with PBS and blocked with 1% BSA in PBS for 1 h at room temperature. Subsequently, the serum samples from immunized mice diluted 1:40 in 0.5% PBS were loaded on the plate and incubated for 90 min at room temperature. The plates were washed three times with PBS, and HRP-conjugated anti-mouse IgG mAb diluted 1:10,000 in 0.5% BSA in PBS was added to the wells. After incubation at room temperature for 1 h, the plates were washed three times with PBS and incubated with 100 μl TMB solution for 5 min. The reaction was stopped by addition of 100 μl 2 M H 2 SO 4 . The OD at 450 nm was measured using a microplate spectrophotometer.
Statistical analysis
Antibody titers were measured in triplicate per mouse. Significant difference in the antibody titers between the immunized groups and the control group was determined by Student's t test using the Instat (version 3.0) program (GraphPad Software, San Diego, CA). Statistical significance was considered at p<0.05, p<0.01 and p<0.001.
RESULTS
Expression and identification of recombinant proteins
To increase the immunogenicity of M2e, eight copies of M2e were constructed and subcloned into the pQE30 expression vector. Expression vectors individually encoding 8×M2e and TAT-8×M2e were constructed and screened by PCR using universal pQE-forward and pQE-reverse primers (data not shown). Positive clones were confirmed by DNA sequencing; the sequence of the insert genes had the same sequence as designed in the proper open reading frame.
Expression of 8×M2e and TAT-8×M2e recombinant proteins was induced by 1 mM IPTG at 37℃. Recombinant proteins were purified using a Ni-NTA column. Purified 8×M2e and TAT-8×M2e proteins showed band sizes of approximately 23 kDa and 27 kDa, respectively ( Fig. 2A and  2B) . The results of Western blotting using anti-His mAb showed 23-and 27-kDa bands consistent with 8×M2e and TAT-8×M2e (Fig. 2C) . Western blotting using influenza H1N1-positive chicken serum also produced the same bands (Fig. 2D) .
Titration of total IgG antibodies against M2e
After immunization of mice with the recombinant proteins, total IgG response to M2e was measured using indirect ELISA. Serum samples taken at 14, 28, and 42 days post-injection (dpi) were used for determination of M2e-specific antibody levels. At 14 dpi, M2e-specific antibody was observed in the 8×M2e and the TAT-8×M2e-immunized groups (Fig. 3A) . After the second immunization, both the 8×M2e and TAT-8×M2e groups showed significantly (p<0.001) higher anti-M2e IgG titers than those in the PBS control group. At 42 dpi, anti-M2e IgG titers showed a further significant (p<0.001) increase in both experimental groups.
IgG subtype antibody analysis
For detailed analysis of the humoral immune response, anti-M2e IgG subtyping was performed through indirect ELISA. M2e-specific IgG1 and IgG2a titers were measured. The antibody appearing pattern of IgG1 to M2e was similar to that of the total IgG (Fig. 3B) . After the first immunization, the 8×M2e group showed a higher titer of anti-M2e IgG1 than the TAT-8×M2e group. However, at the end of the experiment, both the 8×M2e and TAT-8×M2e groups showed significantly (p<0.001) elevated anti-M2e IgG1 titers when compared to the control group.
Unlike the total IgG and IgG1 antibodies, it appeared that the titers of anti-M2e IgG2a showed a significant (p<0.01) increase only in the TAT-8×M2e immunized group (Fig.   Fig. 3 . Measurement of anti-M2e antibody titers. (A) Anti-M2e total IgG, (B) anti-M2e IgG1 and (C) anti-M2e IgG2a titers were determined by ELISA. Statistical significance of experimental groups was determined at * p<0.05, ** p<0.01 and *** p<0.001 by comparison with a control group. 3C). After the second immunization, the anti-M2e IgG2a titer showed a significant (p<0.01) increase in the TAT8×M2e immunized group. After the third immunization, the TAT-8×M2e immunization group showed further significantly (p<0.01) higher anti-M2e IgG2a titers than the control group.
Detection of antibody response recognizing native M2e antigen
There is no guarantee that the antibody-recognizing recombinant 8×M2e protein can interact with native viral M2e protein. High levels of anti-M2e antibody detected by ELISA using recombinant 8×M2e protein sometimes failed to provide protection against influenza infection. M2 protein is scarce on virus particles but abundant in virusinfected cells [10] . Therefore, for measurement of antibodies that can recognize viral M2e protein, MDCK cells seeded on 96-well culture plates were infected with A/NWS/33 virus and incubated with sera taken from vaccinated mice. The results showed that the serum antibodies from the 8×M2e and TAT-8×M2e immunization groups were bound specifically to NWS/33-infected MDCK cells (Fig. 4) . Antinative M2e antibody levels showed a significant increase (p<0.001) at two weeks after the third immunization when compared to the control group. However, the antibody levels were lower than the total IgG level in response to the 8×M2e protein. However, these results suggest that some of the antibodies produced as a result of immunization can react with native M2e on the surface of influenzainfected cells and provide protection against influenza infection.
DISCUSSION
Strain-specific influenza vaccines are produced every year because of the high antigenic variation among influenza viruses. The currently used influenza vaccine contains three subtypes of influenza viruses based on the virus strain predicted to cause the epidemic in the following year. Development of a universal influenza vaccine that provides protection against almost all variant strains of influenza viruses is an attractive approach. Currently, universal influenza vaccines are developed mainly on the basis of the conserved sequences in M2, HA1, HA2, and NP in influenza viruses [7] . Above all, several studies involving M2e vaccines have been conducted. Phase I clinical studies were recently conducted using vaccines with chemical or genetic M2e fusion proteins [23] .
The mechanism of protection provided by the M2e vaccine has also been investigated. Although the anti-M2 antibody does not neutralize infection, it can inhibit influenza virus plaque growth [26] . Antibodies against M2e bind to the M2 protein expressed on the surface of virusinfected cells rather than protein on free viruses. The antibody mediates the killing of infected cells via antibodydependent NK cell activity and prevents spread of the virus to adjacent cells [14] . In this study, recombinant TAT-8×M2e and 8×M2e proteins induced M2e-specific antibody, which recognized the native M2e protein expressed on influenzainfected cells. ELISA for detection of anti-M2e antibody showed significantly elevated antibody titers. The levels of antibodies recognizing native M2e determined by wholecell ELISA also increased only in vaccinated mice. These results suggest that both 8×M2e and TAT-8×M2e proteins can induce high levels of anti-M2e antibodies. These antibodies specific to M2e can react with the native M2e protein present in virus-infected cells and induce ADCC. Therefore, it can be expected that anti-M2e antibodies may play a critical role providing protection from influenza virus infection in vivo.
The transcellular properties of HIV TAT have been described in several studies; several researchers have used TAT for antitumor therapies or vaccine delivery [1, 4, 15, 17] . Antigens fused with PTD are more efficiently presented onto MHC molecules and induce enhanced antitumor immunity [17] . When it fuses with TAT, the C terminus of the nucleoprotein of influenza viruses crosses cell membranes and accumulates inside the trans-Golgi network vesicles. In turn, fusion with TAT promotes efficient presentation via HLA Class I molecules [2] . Th1-type cytokine IFN-γ stimulates IgG2a secretion by B cells [24] . TAT could transfer 8×M2e protein through the cell membrane, where it might be presented on MHC class I molecules. Thus, it could be recognized by CD8 + T cells and promote secretion of IFN-γ and production of IgG2a. In this study, anti-M2e IgG2a showed a greater increase in the TAT-8×M2e vaccine group than in the 8×M2e vaccine group. Because IgG2a mediates ADCC in mice [14] , anti-M2e IgG2a may contribute to protection against influenza virus infection. The observed increase in IgG2a might be due to the presentation of TAT-fused antigens through the cytosolic antigenpresenting pathway and loading onto MHC class I and II molecules. Both CD4 + and CD8 + T cells could recognize this antigen, thus increasing IFN-γ secretion. In turn, the secreted IFN-γ could enhanc eIgG2a secretion by plasmacells. The current study did not include a cytokine assay; therefore, IFN-γ secretion will be confirmed in our next study. Unlike anti-M2e IgG2a, IgG and IgG1 binding to M2e showed a more efficient in crease in the 8×M2e vaccine group than in the TAT-8×M2e vaccine group. These results allow us to infer that the TAT fusion protein is retained in the endosome of the cell or trapped in the nucleus, there by inducing a smaller immune response than 8×M2e [3] . A type of PTD with an amino acid sequence of YGRKKKRRQ-RRR accumulates in the nucleus [22] . Modified PTDs, suchas PTD-4 (YARAAARQARA) or YM-3 (THRLRRRRRR), are known to transduce cargo proteins into the cytoplasm [12, 18] . When fused with target proteins, these modified TATs could induce immune responses more efficiently. Therefore, conduct of further experiments using tamed PTD is needed. Meanwhile, another study using Tat-PTD47-57 (YGRKKRR-QRRR) as a vaccine component reported different results.
In that study, PTD-HBcAg protein induced more anti-HBc IgM antibodies in immunized mice than HBcAg [4] . This discrepancy could be due to the adjuvant used or vaccination route. In the current study, no adjuvant was used and vaccine was delivered only via the transcutaneous route. Therefore, various vaccination methods should be studied in order to improve the efficacy of the TAT-8×M2e vaccine. In summary, a TAT-8×M2e influenza vaccine was generated, and the immune responses of vaccinated mice were studied after transcutaneous vaccination. The vaccine successfully produced antibodies against M2e protein and native M2e. TAT-8×M2e induced significantly higher M2e-specific IgG2a antibody titers than 8×M2e. Vaccines using TAT and M2e could useful for management of influenza virus infections. In addition, TAT could be an invaluable adjuvant for use in vaccines against other viruses.
